Get started
Author

Reema Singh

ORCID: 0000-0002-4630-0207
Observed ORCID: 0000-0002-4630-0207
OpenAlex ID: A5148677626
Response-adapted dasatinib de-escalation strategy compared to upfront Low-dose dasatinib: A prospective cohort study
2026 · Rohan Halder, Reema Singh, et al. · Leukemia Research · 2
AML-949: Upfront Triple Therapy With FLAG-Venetoclax Backbone in Intensive Chemotherapy-Eligible FLT3-ITD Patients With AML: Preliminary Results From a Retrospective Cohort
2026 · Mayank Soni, Rohan Halder, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CML-1655: Superior 96-Week MMR Rates and Safety With Generic Dasatinib 50 mg in Newly Diagnosed CML: Large Real-World Multicenter Study From India
2026 · Sujay Rainchwar, Rohan Halder, et al. · Clinical Lymphoma Myeloma & Leukemia
CML-426: Efficacy and Safety of Asciminib as Second-Line or Later Therapy in Chronic-Phase Chronic Myeloid Leukemia: An Updated Systematic Review and Meta-Analysis
2026 · Shivam Rainchwar, Riya Patil, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CML-426: Efficacy and Safety of Asciminib as Second-Line or Later Therapy in Chronic-Phase Chronic Myeloid Leukemia: An Updated Systematic Review and Meta-Analysis
2026 · Shivam Rainchwar, Riya Patil, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: AML-949: Upfront Triple Therapy With FLAG-Venetoclax Backbone in Intensive Chemotherapy-Eligible FLT3-ITD Patients With AML: Preliminary Results From a Retrospective Cohort
2026 · Mayank Soni, Rohan Halder, et al. · Clinical Lymphoma Myeloma & Leukemia
CML-1655: Superior 96-Week MMR Rates and Safety With Generic Dasatinib 50 mg in Newly Diagnosed CML: Large Real-World Multicenter Study From India
2026 · Sujay Rainchwar, Rohan Halder, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-673: Efficacy and Safety of Teclistamab in Extramedullary Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis
2026 · Shivam Rainchwar, Himanshu Lanje, et al. · Clinical Lymphoma Myeloma & Leukemia
CML-1600: Improving Outcomes in Chronic Myeloid Leukemia With Early Switch to Second-Generation Generic Tyrosine Kinase Inhibitors: A Study From Resource-Limited Settings in Western India
2026 · Reema Singh, Sujay Rainchwar, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-673: Efficacy and Safety of Teclistamab in Extramedullary Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis
2026 · Shivam Rainchwar, Himanshu Lanje, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 10
Citation count: 2
H-index: 1
I10-index:
Year
Topic
Type